Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans

NCT05145309 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-12-17

No results posted yet for this study

Summary

In the DASH (Dietary Approaches to Stop Hypertension) trials, a diet rich in fruits, vegetables, nuts and dairy products, and limited in fat content, was shown to be useful in controlling hypertension, particularly in African Americans (AA). Key components of such a diet are potassium, magnesium, and alkali, each of which has been implicated in lowering blood pressure. In the original IND 116,208, the investigators explored whether potassium-magnesium citrate (KMgCit) as a powder pharmaceutical formulation (dissolved in water before ingestion) could serve as a surrogate for the DASH diet and would lower blood pressure among patients with pre- or Stage I hypertension. Unfortunately, previous studies did not include adequate number of African American patients.

Conditions

Hypertension

Interventions

DRUG

KMgCit

Supplement that provide K, Mg, and citrate

DRUG

Placebo

Power with identical appearance to KMgCit

Sponsors & Collaborators

University of Texas Southwestern Medical Center
lead OTHER

Study Design

Allocation: RANDOMIZED
Purpose: TREATMENT
Masking: DOUBLE
Model: CROSSOVER

Eligibility

Min Age: 21 Years
Sex: ALL
Healthy Volunteers: Yes

Timeline & Regulatory

Start: 2026-11-15
Primary Completion: 2031-12-01
Completion: 2032-12-01
FDA Drug: Yes

Countries

United States

Study Locations

More Related Trials

Entities

Drugs

Placebo

Diseases

Hypertension